Bausch + Lomb, which is listed on both the Toronto and New York stock exchanges, said full separation remains the goal, and that it continues to operate as its own entity. Bausch Health said it would ...

Bausch Health failed to agree a deal to sell its Bausch + Lomb eyecare subsidiary but remains focused on a separation. Bausch + Lomb said Thursday talks held with potential buyers won't result in a ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday. In December, the ...

Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday, sending its U.S.-listed shares ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch + Lomb private with a third-party buyer was one of several options being ...

Jefferies analyst Glen Santangelo downgraded Bausch Health (BHC) to Hold from Buy with a price target of $8, down from $12, after the company ...

In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ...

Modern lifestyles, frequent prescription updates, and continuous lens enhancements drive Japan's spectacle lens market, promoting specialized designs ...